Investors on the quest for market-beating returns often employ the strategy of stock picking. Making informed choices in stocks can greatly amplify your wealth.
The price of IN8bio Inc (NASDAQ: INAB) closed at $0.15 in the last session, up 8.03% from day before closing price of $0.14. In other words, the price has increased by $8.03 from its previous closing price. On the day, 6.59 million shares were traded.
Ratios:
We take a closer look at INAB’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 4.30 and its Current Ratio is at 4.30. In the meantime, Its Debt-to-Equity ratio is 0.31 whereas as Long-Term Debt/Eq ratio is at 0.22.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Laidlaw on March 18, 2024, initiated with a Buy rating and assigned the stock a target price of $7.50.
On August 30, 2022, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $14.
Stock Price History:
Over the past 52 weeks, INAB has reached a high of $1.74, while it has fallen to a 52-week low of $0.11. The 50-Day Moving Average of the stock is -8.45%, while the 200-Day Moving Average is calculated to be -45.36%.
Shares Statistics:
A total of 81.26M shares are outstanding, with a floating share count of 71.27M. Insiders hold about 21.49% of the company’s shares, while institutions hold 17.96% stake in the company.
Earnings Estimates
Current recommendations for the stock of the company come from 3.0 analysts. The consensus estimate for the next quarter is -$0.05, with high estimates of -$0.04 and low estimates of -$0.06.
Analysts are recommending an EPS of between -$0.19 and -$0.24 for the fiscal current year, implying an average EPS of -$0.22. EPS for the following year is -$0.21, with 5.0 analysts recommending between -$0.18 and -$0.27.
